Unicycive Total Assets from 2010 to 2024

UNCY Stock

USD 0.55 0.02 3.77%

Unicycive Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 7.9 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2010-12-31

Previous Quarter

14.2 M

Current Value

7.9 M

Quarterly Volatility

5.9 M

Credit Downgrade

Yuan Drop

Covid

Check Unicycive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unicycive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 77.9 K, Net Interest Income of 429.4 K or Depreciation And Amortization of 386.4 K, as well as many indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Unicycive financial statements analysis is a perfect complement when working with Unicycive Therapeutics Valuation or Volatility modules.

Check out the analysis of Unicycive Therapeutics Correlation against competitors.

For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

Latest Unicycive Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Unicycive Therapeutics over the last few years. Total assets refers to the total amount of Unicycive Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Unicycive Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Unicycive Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unicycive Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 14.19 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Unicycive Total Assets Regression Statistics

	Arithmetic Mean	2,937,448
	Geometric Mean	114,295
	Coefficient Of Variation	202.21
	Mean Deviation	4,271,650
	Median	19,000
	Standard Deviation	5,939,710
	Sample Variance	35.3T
	Range	18.7M
	R-Value	0.62
	Mean Square Error	23.5T
	R-Squared	0.38
	Significance	0.01
	Slope	820,543
	Total Sum of Squares	493.9T

Unicycive Total Assets History

	2024	7.9 M
	2023	14.2 M
	2022	2.8 M
	2021	18.7 M
	2020	204 K

Other Fundumenentals of Unicycive Therapeutics

Intangibles To Total Assets

Unicycive Therapeutics Total Assets component correlations

	Net Tangible Assets	Retained Earnings	Accounts Payable	Total Current Assets	Common Stock	Total Assets	Total Stockholder Equity	Net Debt	Total Liab	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Property Plant Equipment	Current Deferred Revenue
Net Tangible Assets		-0.91	0.93	0.88	-0.3	0.83	0.25	-0.81	0.77	0.19	-0.51	0.82	0.23	-0.24	-0.68	0.68
Retained Earnings	-0.91		-0.81	-0.75	0.18	-0.66	0.15	0.62	-0.95	0.2	0.38	-0.9	0.17	0.1	0.85	-0.88
Accounts Payable	0.93	-0.81		0.78	-0.49	0.79	0.29	-0.71	0.63	0.24	-0.38	0.8	0.26	-0.15	-0.46	0.58
Total Current Assets	0.88	-0.75	0.78		-0.26	0.97	0.5	-0.98	0.71	0.45	-0.41	0.74	0.48	-0.17	-0.64	0.63
Common Stock	-0.3	0.18	-0.49	-0.26		-0.24	-0.28	0.21	-0.07	-0.33	-0.32	-0.04	-0.27	-0.45	0.05	0.11
Total Assets	0.83	-0.66	0.79	0.97	-0.24		0.59	-0.97	0.59	0.55	-0.4	0.76	0.57	-0.19	-0.45	0.59
Total Stockholder Equity	0.25	0.15	0.29	0.5	-0.28	0.59		-0.64	-0.26	0.99	-0.23	-0.04	1.0	-0.22	0.28	-0.29
Net Debt	-0.81	0.62	-0.71	-0.98	0.21	-0.97	-0.64		-0.56	-0.59	0.48	-0.65	-0.62	0.27	0.5	-0.52
Total Liab	0.77	-0.95	0.63	0.71	-0.07	0.59	-0.26	-0.56		-0.31	-0.28	0.85	-0.29	-0.01	-0.94	0.94
Net Invested Capital	0.19	0.2	0.24	0.45	-0.33	0.55	0.99	-0.59	-0.31		-0.11	-0.09	0.99	-0.1	0.33	-0.34
Short Long Term Debt	-0.51	0.38	-0.38	-0.41	-0.32	-0.4	-0.23	0.48	-0.28	-0.11		-0.35	-0.22	0.95	0.3	-0.3
Capital Stock	0.82	-0.9	0.8	0.74	-0.04	0.76	-0.04	-0.65	0.85	-0.09	-0.35		-0.06	-0.14	-0.64	0.93
Net Working Capital	0.23	0.17	0.26	0.48	-0.27	0.57	1.0	-0.62	-0.29	0.99	-0.22	-0.06		-0.21	0.3	-0.31
Short Term Debt	-0.24	0.1	-0.15	-0.17	-0.45	-0.19	-0.22	0.27	-0.01	-0.1	0.95	-0.14	-0.21		0.03	-0.1
Property Plant Equipment	-0.68	0.85	-0.46	-0.64	0.05	-0.45	0.28	0.5	-0.94	0.33	0.3	-0.64	0.3	0.03		-0.8
Current Deferred Revenue	0.68	-0.88	0.58	0.63	0.11	0.59	-0.29	-0.52	0.94	-0.34	-0.3	0.93	-0.31	-0.1	-0.8

Click cells to compare fundamentals

About Unicycive Therapeutics Financial Statements

Unicycive Therapeutics investors use historical fundamental indicators, such as Unicycive Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unicycive Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	14.2 M	7.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC